Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
04:01pm, Tuesday, 26'th May 2026
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: William Blair 46 th Annu
Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social or physical impairment Following initiation of INGREZZA, 96% of patients with mild tardive dyskinesia
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
08:46am, Monday, 18'th May 2026
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adopti
4basebio Announces Appointment of Chief Financial Officer and Board Changes
07:00am, Thursday, 14'th May 2026
Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 M
Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
07:50pm, Tuesday, 12'th May 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
01:45pm, Thursday, 07'th May 2026
Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside
06:24pm, Wednesday, 06'th May 2026
Neurocrine Biosciences delivered a strong Q1, with revenue up 42% and healthy growth in Ingrezza and Crenessity. Enhanced sales efforts could drive Ingrezza upside in 2H'26, while Crenessity has a lon
New algorithms developed by expert clinical endocrinologists provide clear, practical recommendations for healthcare providers to reduce supraphysiologic glucocorticoid (GC) doses in patients with cla
Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript
10:31pm, Tuesday, 05'th May 2026
Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
06:30pm, Tuesday, 05'th May 2026
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compar
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates
06:16pm, Tuesday, 05'th May 2026
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $0.08 per share a year ago.
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
04:01pm, Tuesday, 05'th May 2026
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline)
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
09:00am, Tuesday, 05'th May 2026
SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m.
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
08:30am, Monday, 04'th May 2026
Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported quitting their job due to untreated involuntary movements1 Respondents also reported missing an average of 8 hours of work
